Manus Biosynthesis Inc

Amide Technologies, Inc., based in Cambridge, MA, specializes in on-demand polyamide manufacturing, offering rapid synthesis of peptides that are often difficult to obtain through traditional methods. By leveraging unnatural amino acids and artificial protein backbones, the company bridges the gap between conventional solid-phase peptide synthesis and biological expression, enabling the creation of complex compounds for drug discovery. With a minimum turnaround time of just four days and a 99% on-time delivery rate, Amide accelerates drug development by accepting urgent peptide orders that other vendors may refuse. Their innovative approach provides unprecedented access to large and unusual compounds, facilitating the search for novel therapeutic modalities and enhancing the efficiency of design-build-test cycles for their customers. Generated from the website

Aviceda Therapeutics, based in Cambridge, MA, focuses on harnessing the body's natural immune system to modulate inflammation. The company utilizes highly selective ligands designed for maximum specificity towards targeted immune cells and diseases. By employing nature's design, Aviceda Therapeutics aims to develop innovative therapeutic solutions that enhance immune responses. Their approach emphasizes precision in targeting, which is crucial for effectively addressing various health conditions. Generated from the website

AVI BioPharma is a biopharmaceutical company that develops drugs to treat life-threatening diseases using its patented third generation antisense technology. It has completed clinical trials with its NeuGene antisense drugs in more than 300 subjects, addressing cardiovascular restenosis, infectious diseases, cancer, polycystic kidney disease and drug metabolism. Its most advanced cardiovascular program is for restenosis, where it has completed Phase II trials, evaluating its drug, Resten-NG. AVI BioPharma is also in a Phase II clinical trial with a drug for Hepatitis C infection and its influenza A drug candidate has been confirmed to have efficacy against avian influenza H5N1 in preclinical studies. AVI BioPharma maintains a location in Portland, Ore.